Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards

September 24, 2025 |  

Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across Inizio Evoke, Inizio Engage, and Inizio Medical.

PM360AwardsInizio

We’re proud to announce that our teams across Inizio Evoke, Inizio Engage, and Inizio Medical have been named finalists in six prestigious categories at the 2025 PM360 Trailblazer Awards, which recognize excellence and innovation in healthcare marketing. 

The PM360 Trailblazer Awards honor the most impactful initiatives, strategies, and companies driving change in the healthcare industry across eight core categories. This year, our recognition spans multiple disciplines – highlighting our expertise in artificial intelligence (AI), data analytics, patient and healthcare professional (HCP) education, and persistence/adherence programs, as well as our standing as a top industry partner. 

Our 2025 PM360 trailblazer award finalist categories 

Driving innovation across healthcare marketing 

These finalist recognitions demonstrate how our connected capabilities empower life sciences organizations to achieve greater patient engagement, educational impact, and data-driven decision-making. Our work leverages cutting-edge AI and analytics, compelling creative strategies, and deep scientific expertise to deliver measurable results for our clients and ultimately improve healthcare outcomes. 

Looking ahead 

We are honored to be recognized alongside such inspiring organizations and partners. These six finalist nominations reflect the passion, creativity, and expertise of our teams across Inizio. 

Good luck to all of this year’s finalists – we look forward to celebrating the incredible work shaping the future of healthcare marketing. Stay tuned for the results and follow our updates on LinkedIn. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Healthcare in the age of AI: How will artificial intelligence impact future decision-making?

Authored by: Constanza Salas, Jhon Galindo and Rachel Howard

Therapy Watch launches new tracker covering Postpartum Depression

The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry

Value-based pricing reform: Strengthening the ‘front door’ to the Colombian pharmaceutical market

Authored by: Marc Garcia and Tania Rodrigues

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

New syndicated COPD report now available

Living with COPD 2023

Man vs microbe: the fight against antimicrobial resistance

How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.

Research Partnership Senior Director Andrew Stokes appointed new role as Chief Commercial Officer

With over 20 years' experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.

Case study: How we enhanced the power of a global ATU using our advanced analytics solution, Equity AI

Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.

Article: Creating truly effective communications – the impact of high speed, high octane messaging

In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.

Research Partnership makes two senior appointments to bolster its US and MedTech operations

Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.